Sichenzia Ross Friedman Ference LLP Represents Amarantus BioScience Holdings, Inc. in a $3 Million Registered Direct Offering
February 24, 2016 – New York, NY – Press Release – Sichenzia Ross Friedman Ference LLP announced today that the Firm represented Amarantus BioScience Holdings, Inc. in a $3 million offering of the Company’s Series H Convertible Preferred Stock and Warrants to purchase common stock.
Chardan Capital Markets, LLC acted as sole placement agent for the transaction.
The securities were offered pursuant to an effective shelf registration statement.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey Fessler and Marcelle Balcombe.
- SEC Extends Filing Deadlines for Public Companies and Registered Investment Advisers Affected by COVID-19 - April 1, 2020
- Business Interruption Insurance - April 1, 2020
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $7.7 Million Overnight Bought Offering of Cel-Sci Common Stock - March 26, 2020